このページの翻訳は実験的なもので、現在開発中です。お待ちしております

PharmaEssentia マネジメント

マネジメント基準チェック /34

PharmaEssentia'sの CEO はKo-Chung Linで、 Jan2017年に任命され、の在任期間は 7.58年です。は、会社の株式の1.62%を直接所有しており、その価値はNT$ 3.73B 。経営陣と取締役会の平均在任期間はそれぞれ4.8年と3年です。

主要情報

Ko-Chung Lin

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	7.8yrs
CEOの所有権	1.6%
経営陣の平均在職期間	5yrs
取締役会の平均在任期間	3.2yrs

経営陣の近況

Recent updates

We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings

Aug 20

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Jul 02

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Jul 02

Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

Apr 02

Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

Mar 18

PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 06

Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

Mar 04

PharmaEssentia (GTSM:6446) Is Using Debt Safely

Feb 10

What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 06

PharmaEssentia Corporation's (GTSM:6446) Profit Outlook

Nov 30

CEO報酬分析

PharmaEssentia の収益と比較して、Ko-Chung Lin の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	NT$1b
Mar 31 2024	n/a	n/a	NT$442m
Dec 31 2023	n/a	n/a	-NT$624m
Sep 30 2023	n/a	n/a	-NT$890m
Jun 30 2023	n/a	n/a	-NT$1b
Mar 31 2023	n/a	n/a	-NT$2b
Dec 31 2022	n/a	n/a	-NT$1b
Sep 30 2022	n/a	n/a	-NT$2b
Jun 30 2022	n/a	n/a	-NT$2b
Mar 31 2022	n/a	n/a	-NT$3b
Dec 31 2021	NT$9m	NT$9m	-NT$3b
Sep 30 2021	n/a	n/a	-NT$3b
Jun 30 2021	n/a	n/a	-NT$3b
Mar 31 2021	n/a	n/a	-NT$2b
Dec 31 2020	NT$9m	NT$9m	-NT$2b
Sep 30 2020	n/a	n/a	-NT$1b
Jun 30 2020	n/a	n/a	-NT$862m
Mar 31 2020	n/a	n/a	-NT$856m
Dec 31 2019	NT$9m	NT$8m	-NT$843m

報酬と市場: Ko-Chungの総報酬がTW市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Ko-Chungの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Ko-Chung Lin

7.8yrs

在職期間

NT$9,389,000

報酬

Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ching-Leou Teng	Chairman & Chief Pharmaceutical Officer	12.1yrs	NT$8.49m	1.05% NT$ 2.2b
Ko-Chung Lin	Founder	7.8yrs	NT$9.39m	1.61% NT$ 3.4b
Chan-Kou Hwang	President	no data	NT$8.49m	0.61% NT$ 1.3b
Snow Chang	Accounting Manager & Senior Manager of Finance	9yrs	データなし	データなし
Samuel Lin	VP and Head of Business Operations & Strategy	2.8yrs	データなし	データなし
Lih-Ling Lin	Chief Scientific Officer	2.2yrs	データなし	0.010% NT$ 21.7m
Rachel Lipsitz	VP and Head of Corporate Communications & Advocacy	2.8yrs	データなし	データなし
Roddy Mcilwain	Senior VP and Head of Sales & Marketing	3.8yrs	データなし	データなし
Anjana Pursnani	Senior VP & Head of People	2.8yrs	データなし	データなし
Albert Qin	Chief Medical Officer	7.8yrs	データなし	0.0061% NT$ 12.9m
Narihisa Miyachi	Head of Japan Medical Affairs	6.3yrs	データなし	データなし
Yen-Tung Luan	Chief Operating Officer of Taichung Plant	6.3yrs	データなし	データなし

5.0yrs

平均在職期間

経験豊富な経営陣: 6446の経営陣は経験豊富で経験豊富です（平均在職期間は5年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Ching-Leou Teng	Chairman & Chief Pharmaceutical Officer	12.1yrs	NT$8.49m	1.05% NT$ 2.2b
Ko-Chung Lin	Founder	3.2yrs	NT$9.39m	1.61% NT$ 3.4b
Chan-Kou Hwang	President	9.4yrs	NT$8.49m	0.61% NT$ 1.3b
Jeffrey R. Williams	Independent Director	less than a year	データなし	データなし
Ching-Tsun Liu	Independent Director	less than a year	データなし	0.13% NT$ 268.5m
Jinn-Der Chang	Independent Director	10.6yrs	NT$120.00k	0.029% NT$ 61.0m
Jien-Heh Tien	Independent Director	6.3yrs	NT$120.00k	0.00060% NT$ 1.3m
Ming-Chuan Hsieh	Independent Director	less than a year	データなし	0.0012% NT$ 2.5m
Norio Komatsu	Chairperson of Japan	3.4yrs	データなし	データなし
Shen Yi Li	Director	3.2yrs	NT$95.00k	0.24% NT$ 517.6m
HsuehFang Hsu	Director	less than a year	データなし	データなし
ChenJung Hsiao	Director	less than a year	データなし	データなし

3.2yrs

平均在職期間

経験豊富なボード: 6446の取締役会は経験豊富であると考えられます ( 3年の平均在任期間)。

PharmaEssentia マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Pharmaessentia Corporation Announces Appointments to Board of Directors

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

Less than half of directors are independent

PharmaEssentia Corporation Announces Appointment of Lih-Ling Lin as Chief Scientific Officer

PharmaEssentia Corporation's Subsidiary PharmaEssentia USA Corporation Appoints Meredith Manning to President of the Americas

Less than half of directors are independent

Recent updates

PharmaEssentia Corporation Announces Taiwan MOHW Approves IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors in Principle

We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings

Consensus EPS estimates increase by 55%

Second quarter 2024 earnings: EPS exceeds analyst expectations

PharmaEssentia Corporation to Report Q2, 2024 Results on Aug 13, 2024

Consensus EPS estimates increase by 21%

Price target increased by 39% to NT$581

PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Now 24% overvalued after recent price rise

New minor risk - Share price stability

Pharmaessentia Corporation Announces Appointments to Board of Directors

PharmaEssentia Corporation Provides an Update on Submission of P1101 PhaseIII Clinical Study Protocol for Pre-fibrotic/Early PMFor Overt PMF at Low to Intermediate-1 Risk to China NMPA

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

PharmaEssentia Corporation to Report Q1, 2024 Results on May 13, 2024

PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA

PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia

PharmaEssentia Corporation announced a financing transaction

Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA

PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia

Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B (P1101) for the Treatment of PV in China

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

PharmaEssentia Corporation Receives Civil Lawsuit Decision from Middlesex Superior Court for the Commonwealth of Massachusetts

PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as Besremi®) for the Treatment of Patients with Polycythemia Vera (PV)

Forecast breakeven date moved forward to 2023

PharmaEssentia Corp. Announces Submission of New Drug Registration of BESREMi (Ropeginterferon Alfa-2b) for PV in Hong Kong

Price target increased by 32% to NT$585

Full year 2022 earnings: EPS exceeds analyst expectations

PharmaEssentia Corporation Submits New Drug Registration of BESREMi for PV in Malaysia

PharmaEssentia Corporation Announcement of Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia

Third quarter 2022 earnings: EPS misses analyst expectations

Price target increased to NT$443

Less than half of directors are independent

AOP Files Civil Action Against the PharmaEssentia Corporation in Middlesex Superior Court for the Commonwealth of Massachusetts

PharmaEssentia Corporation Receives "Prior Authorization for Import of Medicines" for Besremi In Macau

Taiwan Ministry of Health and Welfare Approves the Pharmaceutical Plant with GMP to Athenex for KX01 (Tirbanibulin) in the U.S

PharmaEssentia Corporation Announces Approval of New Drug Application (Nda) of Kx01 for Actinic Keratosis (Ak) in Taiwan

PharmaEssentia Corporation Announces Approval of New Drug Application (Nda) of Kx01 for Actinic Keratosis (Ak) in Taiwan

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

PharmaEssentia Corporation Announces Appointment of Lih-Ling Lin as Chief Scientific Officer

PharmaEssentia Corporation Announces Preliminary Results of the Phase II Clinical Trial of Ropeginterferon Alfa-2B(P1101) for the Treatment of PV in China

PharmaEssentia Corporation Announces Submission of Application to TFDA for Change of Study Purpose from IIT to Company-Sponsored Clinical Trial for Treatment of Covid-19 by Ropeginterferon Alfa-2B

PharmaEssentia Corporation Receives Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia(ET)

PharmaEssentia Corporation's Subsidiary PharmaEssentia USA Corporation Appoints Meredith Manning to President of the Americas

Price target increased to NT$357

Less than half of directors are independent

PharmaEssentia Corporation announced a financing transaction

Consensus revenue estimates fall by 29%

PharmaEssentia Corporation, Annual General Meeting, May 27, 2022

Forecast to breakeven in 2023

Consensus forecasts updated

German Federal Court of Justice Upholds AOP's License Rights in Ropeginterferon and PEC's Liability for Damages

Third quarter 2021 earnings released: NT$2.70 loss per share (vs NT$2.42 loss in 3Q 2020)

Forecast to breakeven in 2023

Second quarter 2021 earnings released: NT$2.08 loss per share (vs NT$0.92 loss in 2Q 2020)

Consensus revenue estimates fall to NT$568.0m

Price target decreased to NT$98.00

First quarter 2021 earnings released: NT$2.63 loss per share (vs NT$1.30 loss in 1Q 2020)

AOP Orphan Reports Full Validity of Arbitral Award Against PharmaEssentia

Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

PharmaEssentia Corporation Announces Complete Response Letter for the Drug BESREMi® by US Food & Drug Administration

マネジメント基準チェック /34